Publication

Article

Pharmacy Practice in Focus: Oncology
November 2020
Volume 2
Issue 5

CE: Managing Chronic Immune Thrombocytopenia: Opportunities for Oncology Pharmacists to Optimize Patient Care

This activity is supported by educational grants from Dova Pharmaceuticals, INC. and Cure Media Group.

This activity is supported by educational grants from Dova Pharmaceuticals, INC. and Cure Media Group.

EDUCATIONAL OBJECTIVES

At the completion of this activity, the participant will be able to:

  • Examine the epidemiology, pathophysiology, diagnosis, and impact of chronic immune thrombocytopenia (ITP) among patients with cancer
  • Analyze the latest efficacy and safety data as well as dosing and administration of current pharmacologic treatments of chronic ITP
  • Illustrate the role of the oncology pharmacist in the management of chronic ITP

FACULTY:

Julianne O. Darling, PharmD, BCOP

Outpatient Oncology Clinical Pharmacist , Indiana University Simon Cancer Center, Indianapolis, Indiana

TARGET AUDIENCE: Pharmacists

ACTIVITY TYPE: Application

RELEASE DATE: October 30, 2020

EXPIRATION DATE: November 30, 2021

ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.

Related Videos
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com
Image Credit: © Cavan - stock.adobe.com
Child with cancer -- Image credit: Alexis Scholtz/peopleimages.com | stock.adobe.com
Image Credit: © Rawpixel.com - stock.adobe.com
Image Credit: © RandyJay - stock.adobe.com
WCLC, lung cancer, NSCLC
MARIPOSA Study: Long-Term Outcomes and Next Steps for Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC
The EMPOWER-Lung 1 Trial: Five-Year Outcomes of Cemiplimab Monotherapy in Advanced NSCLC